



Ref no: 376010321
From: Research
Date: 01/03/21
Subject: Hereditary Angioedema (HAE)

REQUEST

Q1. In the past 6 months [latest 6 months available] how many patients have received the following treatments [for any disease]:

- Berinert (Human C1-esterase inhibitor)
- Cinryze (Human C1-esterase inhibitor)
- Takhzyro (Lanadelumab)
- Ruconest (Recombinant human C1-esterase inhibitor)
- Firazyr (Icatibant injection)

Q2. In the past 6 months [latest 6 months available] how many patients have received the following immunoglobulin treatments [for any disease]:

- Cuvitru
- Gammanorm
- Gamunex

- Hizentra
- Hyqvia
- Kiovig
- Octagam
- Privigen
- Subgam

Q3. In the past 6 months, how many patients attended A&E for Hereditary Angioedema (ICD10 code: D84.1) or Angioedema (ICD10 code: T78.3)? Of these patients, how many were treated with the following products:

- Berinert (Human C1-esterase inhibitor)
- Cinryze (Human C1-esterase inhibitor)
- Ruconest (Recombinant human C1-esterase inhibitor)
- Firazyr (Icatibant injection)

RESPONSE

Q1. In the past 6 months [latest 6 months available] how many patients have received the following treatments [for any disease]:

- Berinert (Human C1-esterase inhibitor)
- Cinryze (Human C1-esterase inhibitor)
- Takhzyro (Lanadelumab)
- Ruconest (Recombinant human C1-esterase inhibitor)

- Firazyr (Icatibant injection)

St Helens and Knowsley Teaching Hospitals NHS Trust does not hold the requested information.

Q2. In the past 6 months [latest 6 months available] how many patients have received the following immunoglobulin treatments [for any disease]:

- Cuvitru
- Gammanorm
- Gamunex
- Hizentra
- Hyqvia
- Kiovig
- Octagam
- Privigen
- Subgam

St Helens and Knowsley Teaching Hospitals NHS Trust does not hold the requested information.

Q3. In the past 6 months, how many patients attended A&E for Hereditary Angioedema (ICD10 code: D84.1) or Angioedema (ICD10 code: T78.3)? Of these patients, how many were treated with the following products:

- Berinert (Human C1-esterase inhibitor)
- Cinryze (Human C1-esterase inhibitor)

- Ruconest (Recombinant human C1-esterase inhibitor)
- Firazyr (Icatibant injection)

Less than 5 patients have been admitted via A&E with hereditary angioedema or Angiodema between 1st Feb 2021 and 31st March 2021.

Please note: We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed “lawfully, fairly and in a transparent manner”. It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.